Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

• Published in: Blood Vol. 126; no. 17; pp. 2038 - 2046
• Main Authors: Gill, Joan C., Castaman, Giancarlo, Windyga, Jerzy, Kouides, Peter, Ragni, Margaret, Leebeek, FrankW.G., Obermann-Slupetzky, Ortrun, Chapman, Miranda, Fritsch, Sandor, Pavlova, Borislava G., Presch, Isabella, Ewenstein, Bruce
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 22.10.2015; American Society of Hematology
• Subjects: Adolescent; Adult; Aged; Blood Coagulation Tests; Cross-Over Studies; Female; Follow-Up Studies; Half-Life; Hemostatics; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Recombinant Proteins - administration & dosage; Recombinant Proteins - pharmacokinetics; Thrombosis and Hemostasis; Tissue Distribution; von Willebrand Diseases - drug therapy; von Willebrand Diseases - metabolism; von Willebrand Diseases - pathology; von Willebrand Factor - administration & dosage; von Willebrand Factor - pharmacokinetics; Young Adult

This phase 3 trial evaluated the safety and hemostatic efficacy of a recombinant von Willebrand factor (rVWF) for treatment of bleeds in severe von Willebrand disease (VWD). rVWF was initially administered together with recombinant factor VIII (rFVIII) and subsequently alone, as long as hemostatic f...